Treatment of Acute Coronary Syndromes With Otamixaban - TAO

Description:

The optimal anticoagulation strategy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is unclear. The current trial sought to compare the safety and efficacy of otamixaban, a novel intravenous factor Xa inhibitor, as compared with unfractionated heparin (UFH) + eptifibatide in these patients.